We are delighted that the MITRIS RESILIA valve has now helped more than 100 patients in need of mitral valve replacement.
A robust and growing body of clinical evidence, derived from both clinical trials and real clinical practice, continues to mount in support of aortic and mitral valves with RESILIA tissue. In this issue of the newly renamed RESILIA Tissue Insider, we share the latest RESILIA tissue research, with insight from expert users.
Discover more on RESILIA tissue through the current and past issues below.
This healthcare professional focused booklet explores the latest clinical studies and publications involving the INSPIRIS RESILIA valve and RESILIA tissue through the review of 24 publications and abstracts.
Each reference has been summarized visually over 1 or 2 slides, for you to save time.
*No clinical data are available to evaluate the long-term impact of RESILIA tissue in patients. Additional clinical data for up to 10 years of follow-up are being collected to monitor the long-term safety and performance of RESILIA tissue.
†RESILIA tissue tested against tissue from commercially-available bovine pericardial valves from Edwards in a juvenile sheep model. Flameng, et al. J Thorac Cardiovasc Surg 2015;149:340–5
Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).
An educational website focused on TAVI is underway
Thank you. We will keep you updated when new content is available.